{
    "root": "50ca2c57-aeb0-49e2-8b65-12f779c455f2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ONGENTYS",
    "value": "20250212",
    "ingredients": [
        {
            "name": "OPICAPONE",
            "code": "Y5929UIJ5N"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "LACTOSE, UNSPECIFIED FORM",
            "code": "J2B2A4N98G"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FD&C RED NO. 3",
            "code": "PN2ZH5LOQY"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        }
    ],
    "indications": "ongentys indicated adjunctive treatment levodopa/carbidopa patients parkinson ’ disease ( pd ) experiencing “ ” episodes .",
    "contraindications": "recommended 50 mg administered orally daily bedtime . ( 2.1 ) patients eat food 1 hour least 1 hour intake ongentys . ( 2.1 ) recommended patients moderate hepatic impairment 25 mg orally daily bedtime ; avoid patients severe hepatic impairment . ( 2.2 )",
    "warningsAndPrecautions": "ongentys ( opicapone ) capsules available : • 50 mg hard gelatin capsules , size 1 ; dark blue opaque cap dark pink opaque body ; axially printed “ opc ” “ 50 ” white ink , cap body - bottle 30 child-resistant closure : ndc 64896-403-01 • 25 mg hard gelatin capsules , size 1 ; light blue opaque cap light pink opaque body ; axially printed “ opc ” “ 25 ” blue ink , cap body - bottle 30 child-resistant closure : ndc 64896-402-01",
    "adverseReactions": "ongentys contraindicated patients : concomitant non-selective monoamine oxidase ( mao ) inhibitors [ ( 7.1 ) ] . pheochromocytoma , paraganglioma , catecholamine secreting neoplasms .",
    "indications_original": "ONGENTYS is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.",
    "contraindications_original": "The recommended dosage is 50 mg administered orally once daily at bedtime. ( 2.1 ) Patients should not eat food for 1 hour before and for at least 1 hour after intake of ONGENTYS. ( 2.1 ) The recommended dosage in patients with moderate hepatic impairment is 25 mg orally once daily at bedtime; avoid use in patients with severe hepatic impairment. ( 2.2 )",
    "warningsAndPrecautions_original": "ONGENTYS (opicapone) capsules are available as:\n                        •\n     \n50 mg hard gelatin capsules, Size 1; dark blue opaque cap and dark pink opaque body; axially printed with “OPC” over “50” in white ink, on both the cap and body\n                        - Bottle of 30 with child-resistant closure:  NDC 64896-403-01\n                        •\n     \n25 mg hard gelatin capsules, Size 1; light blue opaque cap and light pink opaque body; axially printed with “OPC” over “25” in blue ink, on both the cap and body\n                        - Bottle of 30 with child-resistant closure:  NDC 64896-402-01",
    "adverseReactions_original": "ONGENTYS is contraindicated in patients with:\n                  \n                     Concomitant use of non-selective monoamine oxidase (MAO) inhibitors [\n                        see \n                        Drug Interactions (\n                        \n                           7.1\n                        \n                        )\n                        ]\n                        .\n                        \n                     \n                     Pheochromocytoma, paraganglioma, or other catecholamine secreting neoplasms."
}